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Correction to: British Journal of Cancer (2002) 87, 61–64. doi: 10.1038/sj.bjc.6600350
Due to an error, the database used in the above study had
interchanged information on sex with those of one of the
participating cohorts. Consequently, some of the results in
the published article were incorrect. The authors have performed
new analyses and the correct data are given below:
In a joint study of future risks for anal and perianal skin cancers
in relation to baseline human papillomavirus (HPV) seropositivity
nested in Norwegian and Finnish cohorts, it turns out that the
information on sex had been interchanged in one of the Norwegian
cohorts.
With correct information on sex, HPV 16 seropositivity
conferred an increased risk of anal/perianal cancer of 3.6 (95%
CI¼1.3–10). Overall, 27% of the female and 31% of the male cases
were seropositive for HPV 16. Similar figures for HPV 18 were 27%
and 8%, respectively. By dichotomisation on age and lag in the
Norwegian cohort, we found that HPV 16 seropositive men above
45 years of age had an increased risk (OR¼16; 95% CI¼2.6–96)
as did subjects with less than 10 years lag (OR¼6.9; 95% CI¼
1.7–27).
The corrected data are given below (Table 1).
The authors apologise for any inconvenience this may have
caused. For a complete list of corrections to the text of the article,
please contact tone.bjorge@oslo.online.no
Table 1 Risk of developing anal and perianal skin cancer (n¼28) according to the presence of IgG antibodies to different human papillomavirus (HPV)
types; case – cohort design*
% Positive
Without adjustment
for the other HPV types
With adjustment
for the other HPV types
HPV type Cases (n¼28) Controls (n¼1500) OR 95% CI OR 95% CI
HPV 16
a 29 8 3.7 1.5–9.5 3.6 1.3–10
HPV 18
b 18 7 2.9 0.9–9.2 2.9 0.8–10
HPV 33
b 21 11 1.5 0.5–4.3 1.0 0.3–3.2
HPV 16, 18 or 33 50 19 4.0 1.7–9.4 4.5 1.9–11
HPV 73
b 4 7 0.4 0.1–3.1 0.3 0.0–2.1
aHPV 16: cut-off level, 354.
bHPV 18, 33 and 73: cut-off level, 100. *Sex (two categories), age (three categories), time of serum sampling (four categories) and serum bank/area of
residence (five categories; Finland, Oslo county, Finnmark county, other Norwegian counties and Red Cross blood donors) were adjusted for in all models.
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